-transparent.png){kind=logo}
The authors summarise their experience of four clinical studies with a negative oral contrast agent for magnetic resonance imaging of the abdomen and pelvis. 140 patients were enrolled in the studies. These were partly comparative studies pre- and post-contrast, partly at 0.5 and 1.5 T, partly pre-injection and post-injection of glucagon. All patients received 800 ml of a suspension of oral magnetic particles "OMP". The distribution of this contrast agent was homogeneous throughout the entire GI tract. A complete or partial signal void was observed in all patients in T1, T2-, and intermediately weighted images. Generally, diagnostic information was higher after contrast. Artifacts caused by peristalsis and movement of the diaphragm were fewer after contrast. After contrast metallic artifacts were observed in a minority of patients. Adverse events after contrast were minimal; they included nausea and vomiting.
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
January 1993,
Journal of magnetic resonance imaging : JMRI,
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
January 1992,
Acta radiologica. Supplementum,
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
January 1988,
Acta radiologica (Stockholm, Sweden : 1987),
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
May 1991,
Acta radiologica (Stockholm, Sweden : 1987),
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
July 1996,
Academic radiology,
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
August 1990,
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
February 2006,
Magnetic resonance imaging,
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
December 1988,
Radiology,
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
December 1998,
Pharmaceutica acta Helvetiae,
P A Rinck, and
G Myhr, and
O Smevik, and
A Børseth
January 1989,
Radiologia diagnostica,
